Critical Limb Ischemia Clinical Trial
Official title:
Recombinant SeV-hFGF2 / dF Injection (BF30) Single-dose Therapy in Patients With Peripheral Arterial Occlusive Disease, a Dose Escalation, Safety, Tolerability Phase I Clinical Trial
Lower extremity arteriosclerosis obliterans is due to the formation of atherosclerotic plaque
in the lower extremities, resulting in the stenosis and occlusion of the artery, leading to
chronic ischemia of the limbs. Although bypass surgery and angioplasty ( or interventional
therapy ) are effective methods for vascular treatment in patients with PAD to revascularize,
a significant proportion of patients with the arterial disease are not eligible for direct
arterial surgery. Meanwhile, there are many patients who suffer from diffuse arterial disease
or severe peripheral disease not suitable for interventional therapy. Stimulation of
arteriogenesis( blood bypassing the occluded arteries through a large number of collateral
vessels ) and angiogenesis ( generating new small blood vessels ) have become the focus of
research.
Our recombinant SeV-hFGF2/dF injection (R&D code BF30 ) uses the human basic fibroblast
growth factor ( FGF2 ) gene to express the target protein FGF2 locally by intramuscular
injection. The preparation can efficiently express FGF2 in infected cells and secrete it to
the periphery and be fixed in the intercellular substance. Since FGF2 is in the upstream
regulatory pathway of VEGF, HGF and other factors, it can regulate the coordinated expression
of these cytokines related to the growth and function of new blood vessels, and finally,
produce mature blood vessels.
To evaluate the safety ( tolerance), pharmacokinetics (PK), biological activity, and
immunogenicity of BF30 in patients with lower extremity arterial occlusive disease, and to
explore clinical benefits.
MAIN OBJECTIVE: To evaluate the safety ( tolerability ) of single-dose BF30 in patients with
lower extremity arterial occlusive disease, and to provide evidence for the dose of
subsequent clinical trials.
Secondary objective: To explore the pharmacokinetics (PK), biological activity, the
immunogenicity of BF30, and to initially explore clinical benefits.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
| Recruiting |
NCT04110964 -
Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
|
Phase 1 | |
| Not yet recruiting |
NCT03994666 -
Cell Therapy in Critical Limb Ischemia
|
Phase 2 | |
| Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
| Not yet recruiting |
NCT02498080 -
Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia
|
N/A | |
| Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
| Recruiting |
NCT02239419 -
Evaluation of Carbothera in the Treatment of Foot Ulcers
|
N/A | |
| Recruiting |
NCT01938872 -
Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia
|
N/A | |
| Active, not recruiting |
NCT01211925 -
Distal Venous Arterialisation of Ischemic Limb
|
Phase 2/Phase 3 | |
| Completed |
NCT02454231 -
Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)
|
Phase 2/Phase 3 | |
| Completed |
NCT01758874 -
Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
|
Phase 2 | |
| Completed |
NCT02475200 -
Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
|
||
| Recruiting |
NCT04583436 -
Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia
|
N/A | |
| Completed |
NCT04071782 -
Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore
|
N/A | |
| Completed |
NCT03669458 -
Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.
|
N/A | |
| Not yet recruiting |
NCT06007469 -
Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
|
||
| Recruiting |
NCT04110327 -
An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
|
||
| Completed |
NCT02260622 -
Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
|
Phase 2 | |
| Recruiting |
NCT02054416 -
External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality
|
N/A | |
| Not yet recruiting |
NCT01446055 -
Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia
|
Phase 1/Phase 2 |